论文部分内容阅读
目的观察长春瑞滨联合卡培他滨治疗晚期乳腺癌的临床疗效和毒副反应。方法长春瑞滨25mg/m2快速静脉滴注,第1,8天;卡培他滨1000mg/m2,2次/d,第1～14天,21d为一周期,所有病例均接受至少2个周期的化疗。结果28例患者入组,均为复治病例,均可行疗效及毒性评价,其中完全缓解1例(3.6%),部分缓解12例(42.8%),总有效率46.4%。主要毒副反应为骨髓毒性及手足综合症,均相对较轻。结论长春瑞滨联合卡培他滨方案治疗晚期乳腺癌有较好的疗效,毒副反应小,值得临床进一步研究。
Objective To observe the clinical efficacy and toxicity of vinorelbine plus capecitabine in the treatment of advanced breast cancer. Methods vinorelbine 25mg / m2 rapid intravenous infusion, day 1,8; capecitabine 1000mg / m2, 2 times / d, 1 to 14 days, 21d for a cycle, all patients received at least 2 cycles Chemotherapy. Results All the 28 patients were enrolled in the re-treatment group. All of them were effective and toxic. Among them, complete remission was achieved in 1 case (3.6%), partial remission in 12 cases (42.8%) and total effective rate was 46.4%. The main side effects are myelotoxicity and hand-foot syndrome, which are relatively mild. Conclusion Vinorelbine combined with capecitabine in the treatment of advanced breast cancer has a better curative effect with less side effects and deserves clinical further study.